Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.

Amphastar vs. BioCryst: A Decade of Cost Dynamics

__timestampAmphastar Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.
Wednesday, January 1, 2014159205000122000
Thursday, January 1, 20151741720001896000
Friday, January 1, 20161509760002699000
Sunday, January 1, 20171493800001702000
Monday, January 1, 2018187681000471000
Tuesday, January 1, 20191904340004101000
Wednesday, January 1, 20202065060001676000
Friday, January 1, 20212380290007264000
Saturday, January 1, 20222501270006594000
Sunday, January 1, 20232932740004661000
Loading chart...

Igniting the spark of knowledge

Cost of Revenue Trends: Amphastar vs. BioCryst

In the competitive landscape of pharmaceuticals, understanding cost dynamics is crucial. Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have shown distinct trajectories in their cost of revenue from 2014 to 2023. Amphastar's cost of revenue has surged by approximately 84%, from $159 million in 2014 to nearly $293 million in 2023. This growth reflects their expanding operations and market reach. In contrast, BioCryst's cost of revenue, while significantly lower, has seen a more modest increase, peaking at $7.3 million in 2021 before slightly declining to $4.7 million in 2023. This disparity highlights the different scales and strategies of these companies. Amphastar's consistent upward trend suggests robust growth, whereas BioCryst's fluctuations may indicate strategic shifts or market challenges. These insights provide a window into the operational efficiencies and market strategies of these pharmaceutical players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025